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Abstract (250 word limit) 
Drugs are commonly used in combinations larger than two for treating bacterial infection. 
However, it is generally impossible to infer directly from the effects of individual drugs 
the net effect of a multi-drug combination. Here we develop a mechanism-independent 
method for predicting the microbial growth response to combinations of more than two 
drugs. Performing experiments in both gram-negative (Escherichia coli) and gram-
positive (Staphylococcus aureus) bacteria, we demonstrate that for a wide range of drugs, 
the bacterial responses to drug pairs are sufficient to infer the effects of larger drug 
combinations. To experimentally establish the broad applicability of the method, we 
employ drug combinations comprised of protein synthesis inhibitors (macrolides, 
aminoglycosides, tetracyclines, lincosamides, and chloramphenicol), DNA synthesis 
inhibitors (fluoroquinolones and quinolones), folic acid synthesis inhibitors 
(sulfonamides and diaminopyrimidines), inhibitors of cell wall synthesis, polypeptide 
antibiotics, preservatives, and analgesics. Moreover, we show that the microbial 
responses to these drug combinations can be predicted using a simple formula that should 
be widely applicable in pharmacology. These findings offer a powerful, readily 
accessible method for the rational design of candidate therapies using large drug 
combinations. In addition, the accurate predictions of this framework raise the question of 
whether the multi-drug response in bacteria obeys statistical, rather than chemical, laws 
for combinations larger than two. 
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Introduction 
Combinations of three or more drugs have been studied in both clinical and 
laboratory settings as potential treatments for severe microbial infections
1-4. Drug 
interactions, including those that are clinically beneficial, have typically been studied 
using descriptive, rather than predictive, approaches that quantify the effects of a given 
drug pair on growth
5-7. For example, two drugs whose effects on microbial growth 
counteract one another, when used in combination, are known as antagonistic, whereas 
drugs whose potencies are significantly increased in combination are referred to as 
synergistic. As a result of these interactions, the effects of drug combinations cannot, in 
general, be predicted based on the effects of the drugs alone
7. While combinations of two 
drugs have been studied extensively, little is known about the way more than two drugs 
combine to yield higher-order effects on bacterial growth, which is the relevant clinical 
outcome in treatments of bacterial infections. Here, we ask if it is possible to understand 
and predict the effects of these larger drug combinations without relying on specific 
mechanistic details but on principles shared by a large number of biological systems.  
For example, consider a classic 3-drug combination of chloramphenicol (a protein 
synthesis inhibitor), ofloxacin (a fluoroquinolone DNA synthesis inhibitor), and 
trimethoprim (a folic acid synthesis inhibitor) at the following concentrations: 
[Chloramphenicol]=1.5 μg/mL, [Ofloxacin]=40 ng/mL, and [Trimethoprim]=0.3 μg/mL. 
The growth rate of E. coli treated with each drug alone is about 0.58, 0.47 and 0.39 
(normalized by the growth of untreated cells), respectively.  Combining chloramphenicol 
and ofloxacin leads to a growth rate of 0.53, which is significantly higher than expected 
from a naive multiplication of the single drug rates (0.27) and consistent with previously 
observed antagonism between DNA synthesis inhibitors and protein synthesis inhibitors
8.  
On the other hand, combining ofloxacin with trimethoprim completely eradicates growth 
(growth < 0.01, as compared to 0.18 expected from single drug growth rates), consistent 
with previously reported synergy between trimethoprim and fluoroquinolones
9.  Finally, 
the combination of chloramphenicol and trimethoprim leads to a growth rate of 0.16, 
slightly smaller than the 0.23 predicted from single drug growth rates. The effects of all   3
three pairs of drugs differ significantly from that predicted by multiplication of single 
drug effects. There is, therefore, seemingly little hope that such an assumption of 
independence will be useful when all three drugs are combined and the chemical 
complexity of the problem is increased. Surprisingly, the growth rate in the presence of 
all three drugs (0.11) is equal to the product of single drug growth rates, suggesting that 
the drugs act independently.  Why have the previously strong interactions between drug 
pairs been eliminated when the three drugs are combined, leading to a cocktail of 
effectively independent drugs? One hypothesis would be that the net effect of the drug 
combination arises from compensatory interactions that can only be measured when all 
three drugs are present. Alternatively, the net effect could follow directly from the 
accumulation of interactions between pairs of drugs. We wish to answer this question 
using a quantitative framework to provide insight into how the cell integrates signals 
from larger drug combinations.  
To tackle this question for a wide range of drug combinations, we develop a 
mechanism-independent model to quantify the relative contributions of combined 
chemical exposure—that is, 1-drug effects, 2-drug effects, and in general, N-drug 
effects—to the multi-drug growth response. We construct the model using a common 
statistical method, entropy maximization, which ensures it does not incorporate 
unwarranted statistical structure. We then test predictions of this framework using two 
species that represent gram–negative (Escherichia coli) and gram–positive 
(Staphylococcus aureus) bacteria. This predictive framework is a potentially powerful 
tool for studying multi-drug effects, even without knowledge of the underlying network 
structure, molecular dynamics, or any other intracellular details. 
 
 
Results  
Response of E. Coli to Single Drugs and Drug Pairs 
  First, we measured the growth of E. coli in the presence of a single drug and then 
pairs of drugs by growing liquid cultures in Luria-Bertani media. We used a large variety 
of drugs, including several classes of protein synthesis inhibitors (with 30S and 50S 
ribosomal targets), DNA synthesis inhibitors (fluoroquinolones), folic acid synthesis   4
inhibitors, and analgesics (Table S1). Using time series of optical density measured 
directly from a 96-well plate reader, we estimated growth with nonlinear least-squares 
fitting (Methods).  We define g1...N to be the measured growth rate of cells in our 
experiments exposed to a treatment with N drugs, D1, D2, ..., DN. All growth rates are 
normalized by growth rate in the absence of drugs.  To understand the relationship 
between pairwise drug interactions and the net drug interaction between more than two 
drugs, we first asked whether one can estimate the growth response to three or four drugs 
using only our experimental measurements of single drug, gi, and two-drug, gij, growth 
rates (Fig. 1).   
  We model the effect of each drug, Di, using an associated stochastic variable, Xi.  
Specifically, we assume that the measured (normalized) growth rate is equal to the mean 
(i.e. expectation) value of that random variable, gi=<Xi>.  Similarly, in the presence of 
two drugs, i and j, the normalized growth is taken to be gij=<Xi Xj> and, in general, the 
normalized growth in presence of a combination of N drugs, g1...N, equals the mean value 
<X1…XN> of the product of the Xi’s.  The relevant experimental observable, growth, is 
associated with the moments (or joint moments) of the variables Xi, not to the stochastic 
variables themselves. By construction, then, drug interactions are represented as 
correlations between these abstract variables.  In this framework, an absence of 
correlation between variables Xi and Xj indicates that the drugs do not interact, and 
therefore gij is equal to the product of the independent growth rate gi and gj. In the 
absence of interactions between the drugs, this statistical model is equivalent to the well-
known Bliss independence model
5,7 in pharmacology. 
  
Drug interactions defined as a mechanism-independent statistical problem  
  To characterize the apparent interactions between drugs (i.e. synergies and 
antagonisms), we introduce a probability density P(x) =P(x1, x2, …, xN) that describes the 
joint distribution of these random variables. Unfortunately, this probability distribution 
P(x) is not directly accessible, though as we will show, it can be estimated using 
experimental data. Specifically, we wish to estimate the probability density P(x) using 
only the growth rate data in response to single drugs and drug pairs.  We call this estimate 
Ppair(x), because it depends only on the interactions between drug pairs and the effects of   5
the drugs alone. Ppair(x) provides a picture of how the two-drug interactions would 
accumulate if there were no additional drug interactions, such as those requiring the 
presence of all three or four drugs. Of course, Ppair(x) will provide a good approximation 
to the true P(x) and, ultimately, to experiments only if the effects of higher order 
interactions (3-drug, 4-drug) are negligible. 
 To  estimate  Ppair(x) from experiments, we use entropy maximization
10,11 (Fig 1), 
a well-established statistical technique that guarantees that Ppair(x) contains only the 
information from our 1-drug and 2-drug data sets (see Supporting Online Material). In 
this case, the form of the maximum entropy distribution is given by  
Ppair(x)=
1
Z
exp hixi
i  + Jijxixj
i<j 


 


  
where subscripts label the components of x, and h and J represent the collection of free 
parameters determined by the data (Supporting Online Material, Figs. S3-S7), and Z is 
the normalization constant (i.e. partition function). It is straightforward to determine the 
parameters hi and Jij from our measurements of single and pairwise drug effects at each 
dosage (Supporting Online Material).  
 
3- and 4-Drug Interactions Arise from the Accumulation of Pairwise Interactions  
Using the estimated distribution Ppair(x), one can easily calculate the expected 
growth response to a larger combination of drugs, g1,..N=<X1X2…XN>, where brackets 
represent an average using the distribution Ppair(x). This prediction would match 
experimental results only if the net effects of the drug combination arise entirely from the 
accumulation of pairwise interactions but not from higher drug-interactions. To test this 
framework, we calculated expected growth response to various combinations of N drugs.  
We focus on the N=3 and N=4 cases, which are near the upper limit of current multi-drug 
treatments in clinical settings. We then directly measured bacterial growth in the presence 
of these drug combinations and compared them to our expected results using the 
estimated distribution Ppair(x) (Figures 2, S12-S16).  Notably, the relationship between 
the N-drug response and the responses to single drugs and drug pairs—a relationship 
governed by the distribution Ppair(x) calculated from entropy maximization—is well-  6
described by simple algebraic expressions
12 (Supporting Online Material). For example, 
the response to three drugs (gijk) is given by 
gijk = gigjk +gjgik +gkgij −2gigjgk, 
and the response to four drugs (gijkl) is given by 
gijkl = gijgkl +gikgjl +gilgjk −2gigjgkgl 
These well-known formulas are fully consistent with our numerical maximum entropy 
predictions and can be derived from the famous Isserlis theorem
12 in the specific case 
when Ppair(x) is a Gaussian distribution.  The simple expressions provide a way to predict 
the effect of a drug combination on growth without using the sophisticated maximum 
entropy framework. However, the fact that these simple formulae yield predictions 
identical (Figure S8) to those from maximum entropy calculations guarantees that they 
contain no hidden correlations, only correlations from measured pairwise and single drug 
effects. 
Figure 2A shows representative data collected from bacteria exposed to various 
concentrations of the combination of three antibiotics, erythromycin, doxycycline and 
lincomycin. All three drugs inhibit protein synthesis, erythromycin by inhibiting 
translocation of peptidyl tRNA, doxycycline by disrupting aminoacyl-t-RNA binding to 
the ribosome, and lincomycin by inhibiting enzymatic activity of peptidyl transferase. We 
previously found that lincomycin is antagonistic with both doxycycline and 
erythromycin, while the latter two drugs are synergistic (Figure S3). However, since the 
mode of action is similar for the three drugs, it is possible that these mechanisms might 
interact in a unique way when all three drugs are present.  Therefore it is not clear 
whether the overall effect could be predicted solely from the accumulation of the 
measured pairwise interactions. Interestingly, Figure 2A demonstrates that the pairwise 
interactions are indeed sufficient to accurately predict the growth response to the 
combination of these three protein synthesis inhibitors.  
Next, we tested this approach using chloramphenicol, erythromycin, and 
salicylate. The former two drugs are protein synthesis inhibitors.  The binding of 
chloramphenicol to its ribosomal target has been shown to enhance the ribosomal binding 
of erythromycin
13, and it is therefore not surprising that we found chloramphenicol and 
erythromycin to be synergistic when used together. Salicylate, the active component of   7
the analgesic aspirin, is known to be a potent inducer of a multi-drug efflux pump that 
contributes to E. coli’s resistance to chloramphenicol 
14. Consequently, it is also not 
surprising that chloramphenicol and salicylate are strongly antagonistic. While 
interactions between salicylate and erythromycin have not been studied, we found them 
to be weakly antagonistic.  What happens when the three drugs are combined together? A 
priori, one might expect a novel effect when all three drugs are present.  The presence of 
salicylate decreases the intracellular concentration chloramphenicol, which might then 
decrease the binding affinity of erythromycin in a manner that depends on the dosages of 
salicylate and chloramphenicol. However, we find that pairwise interactions again yield 
accurate predictions of multi-drug effects (Fig. 2B).   
We found similar results for three additional 3-drug combinations and also for 
two 4-drug combinations.  In all experiments, the predictions from the pairwise 
experiments provide accurate descriptions of the data (Figs. 2C, S12-S16, Table 1).   
Interestingly, although most pairs of drugs interact either synergistically or 
antagonistically, we found that some 3-drug combinations, such as doxycycline-
erythromycin-lincomycin, act almost independently in larger combinations, while others, 
such as chloramphenicol-salicylate-ofloxacin, display extremely strong interactions and 
deviate significantly from Bliss independence (Fig S10). Using standard model selection 
techniques (Supporting Online Material), we verified that the Bliss independence model 
may be applicable for select drug combinations, but as a whole, the pairwise model (R
2 = 
0.90) performs significantly better than the independent model (R
2=0.33) for describing 
the effects of three or four drugs in combination (Table 1).  In addition to the previous 
results, which include drug combinations over a large range of drug dosages, we also 
surveyed various multi-drug interactions by performing 5 combinatorial experiments 
yielding 93 unique 3-drug combinations and a total of 120 unique dosage combinations 
(SI, Figs S17, S18, Table S2). We included a large range of drug types, including pain 
relievers, food preservatives, and inhibitors of DNA synthesis, folic acid synthesis, cell 
wall synthesis, and protein synthesis. Again, the pairwise model (R
2=0.95) significantly 
outperforms the independent model (R
2=0.29) and provides an excellent description of 
the data.  Overall, these results suggest that for a wide range of antimicrobial drugs, the   8
net effect of a drug combination is dominated by the accumulation of pairwise drug 
interactions, independent of the modes of action of the specific drugs involved. 
 
 
 
The Effects of 3-Drug Combinations in Staphylococcus aureus 
Since this approach does not rely on assumptions about molecular mechanisms, it 
should then be applicable to other bacterial species. As a model system, we used the 
bacterium Staphylococcus aureus, a common source of clinical infections. S. aureus are 
gram-positive bacteria whose response to antibiotics differ substantially from that of E. 
coli 
15.  As for E. coli, we first measured the growth of S. aureus in response to three 
drugs: tetracycline, kanamycin, and erythromycin.  All three drugs inhibit protein 
synthesis via different mechanisms.  We performed the measurements for all drugs alone, 
and then repeated the measurement for all pairs of drugs.    
Using the single drug and pairwise measurements, we then estimated the 
distribution Ppair(x), which allowed us to calculate the expectation of the growth response 
to the 3-drug combination.  We tested these predictions by comparing them with direct 
measurements of S. aureus growth in the presence of all three drugs. Remarkably, Figure 
2D demonstrates that the mechanism-independent framework correctly predicts the 
experimentally measured growth response to multi-drug exposure in S. aureus based 
solely on the responses to single and drug pairs.   
 
Quantifying the Contribution of Pairwise Interactions to the Multi-Drug Response 
Overall, these results suggest that the integrated growth response of bacteria to 3-
drug and 4-drug combinations can be directly inferred from the measured interactions 
between drug pairs. The data and the predictions are in excellent agreement, and the 
pairwise model performs significantly better than the Bliss independence model 
according to model selection techniques.  However, the maximum entropy framework
16,17 
provides an additional metric that allows us to further quantify exactly how well the 
pairwise model captures deviations from independence. To do so, we used the maximum 
entropy distributions Pi (i=1,2,3), which are consistent with the measured effects of all   9
combinations composed of up to i drugs, to calculate the fraction of total correlations, fc, 
captured by the pairwise hypothesis (Table 2).  Strikingly, this analysis demonstrates that 
there is very little additional information (~ 3%) encapsulated by pure three-drug 
interactions.  The answer to our original question is therefore surprising: the combined 
effects of these 3-drug combinations follow almost entirely from the effects of the drugs 
alone and in pairs.  
 
How Exactly Do Pairwise Interactions Accumulate? 
Our results demonstrate that for a large variety of antimicrobial drug 
combinations, no new apparent chemical interactions arise when three or four drugs are 
combined together.  Instead, the net effect of the drug combination arises from the 
cumulative effect of the pairwise interactions. Given this drastic simplification, what 
outcomes are possible when drugs are combined at specific dosages?  Surprisingly, there 
are still numerous ways that pairwise interactions can be combined to yield higher-order 
drug combinations (Fig. 3), even without requiring novel 3-drug or 4-drug effects.  For 
example, weak synergistic interactions between drug pairs, such as those between 
chloramphenicol and erythromycin or erythromycin and trimethoprim, can combine to 
yield a cumulative effect that is strongly synergistic at particular doses (Fig. 3A).   
Conversely, as we saw with the initial example of chloramphenicol, ofloxacin and 
trimethoprim (Fig. 3B), strong pairwise drug-drug interactions can combine to yield a 
cumulative drug effect weaker than or similar to the strongest pairwise interaction (Fig. 
3D).  In the case of salicylate, chloramphenicol, and ofloxacin, which interact 
antagonistically when used in pairs, the net result is an antagonistic 3-drug effect whose 
magnitude is similar to that of the pure salicylate-ofloxacin interaction (Fig. 3C).  In all 
cases, the net effect can be predicted using only the response to drug pairs (Fig. 3A-F), 
illustrating that a wide range of cumulative effects are possible depending on the dosages 
of each drug, even in the absence of pure 3-drug or 4-drug interactions.  Overall, these 
results offer a mechanism-independent framework for predicting the cooperative effect of 
drug combinations on bacterial growth using only the information from the response to 
isolated drugs and drug pairs. 
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Discussion 
Our experiments reveal that for many antimicrobial drug combinations, 
interactions involving exactly three or more drugs do not appreciably contribute to the 
overall effect of the combination. The results are complementary to detailed, mechanistic 
models because they impose an upper limit on how much mechanistic information is 
required to predict bacterial growth. Mechanistic and empirical approaches remain 
essential to characterize the effects of specific drug pairs
18-23.  Remarkably, however, our 
results reveal that additional information is often not required to predict the effects of 
larger combination of drugs. Consequently, these findings may provide a powerful 
strategy for the rational design of candidate therapies using large drug combinations, 
even when full mechanistic descriptions are not available. 
Nevertheless, the approach does have practical limitations.  First, the distribution 
Ppair(x) (or equivalently, the single drug and two-drug effects, gi, and gij) measured for a 
particular bacterial strain cannot, in general, be used to predict the multi-drug response in 
a different strain.  Using this approach to screen for multi-drug combinations to combat 
drug-resistant mutants, for example, would require measurements of the relevant two-
drug effects in each specific strain.  Secondly, it is important to note that we chose 
maximum entropy as a systematic way to incorporate deviations from Bliss independence 
without adding spurious statistical structure. However, there may exist other pairwise 
models that can also be used to estimate the effects of larger drug combinations.  Our 
primary finding is that at least one such pairwise model exists that provides excellent 
predictive power.  Finally, one can design ad-hoc examples where any pairwise model is 
likely to fail.  For example, if one drug were an enzyme that required two substrates, then 
the combination of the enzyme with both substrates might yield a completely novel three-
body interaction that could not be predicted from the pairwise effects.  Interestingly, 
however, we do not find evidence for such strong three-body interactions in any of our 
experiments. 
  Previous studies have also used pairwise approximations in other contexts, but the 
underlying variables represented the dynamics of specific cellular components or other 
physical entities such as proteins or neurons
24-30. Most notably, a recent study in cancer   11
cells demonstrated that the expression of some proteins in response to combinations of 
drugs can be predicted from their responses to smaller drug combinations
24. Elucidating 
the biological connection between these results, at the level of individual proteins, and 
the integrated responses of entire cells, such as growth, remains an intriguing question for 
future work. Unfortunately, fully mechanistic models of the transcriptional, metabolic, 
and post-translational networks governing the multi-drug response may be intractable, 
highlighting the need for phenomenological or statistical models to bridge this gap. To 
circumvent the difficulties associated with building a mechanistic model, we have 
formulated the problem using a mechanism-independent statistical approach. By using 
coarse-grained stochastic variables, Xi, whose moments <X1..Xn> reflect the effects of a 
combination of N drugs, we have replaced large, intractable mechanistic models with a 
remarkably small statistical model of interacting drugs.  Although the variables do not 
have a direct microscopic interpretation, they do offer a very powerful tool for inferring 
the relationship between the N-drug response and the response to drug pairs.  Moreover, 
we find that simple formulae can yield accurate predictions as well, making the approach 
widely applicable and easy to implement. From a basic science perspective, the picture 
emerging from our analysis is surprising because it suggests that the chemical complexity 
underlying the cellular response to drug combinations often does not exceed that of drug 
pairs. These findings therefore raise the possibility that the multi-drug response in 
bacteria obeys statistical, rather than chemical, laws for combinations larger than two. 
Finally, because our findings do not depend on details of any specific cellular system, 
they offer a powerful predictive framework that may be applicable to other bacteria and 
even to eukaryotes. 
 
 
Methods 
Bacterial strains 
We used the wild-type BW25113 strain for all experiments on E. coli (Δ(araD-araB)567, 
ΔlacZ4787(::rrnB-3), λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514)
31.   We used the clinically-
isolated strain Newman for all experiments on S. aureus
32.   
   12
 
 
Drugs 
We prepared all drug solutions from solid stocks (see Figure S1 for list of drugs, their 
classes, and mode of action). All antibiotic stock solutions were stored in the dark at -20 
degrees C in single-use daily aliquots. All drugs were thawed and diluted in sterilized 
broth for experimental use.   
 
Media 
We used Lennox LB broth (Fisher) for experiments on E. coli and Tryptic Soy Broth 
(BD) for experiments on S. aureus. 
 
 
Growth Conditions and Drug Treatments 
For both E. coli and S. aureus experiments, we inoculated 3 mL fresh media with a single 
colony and grew the cells overnight (12 h) in 14 mL culture tubes at 30 degrees C, with 
shaking at 200 rpm. Following overnight growth, stationary phase cells were diluted 
(5000 fold for E. coli, 20000 fold for S. aureus) in media and grown for an additional 2 h 
at 30 degrees C, with shaking at 200 rpm. We then transferred 195 μl cells plus media to 
96-well plates (round bottom, polystyrene, Corning) and to each well added a given 
combination of 1, 2, 3, or 4 drugs.  Specifically, we set up a two-dimensional matrix of 1-
, 2-, 3-, or 4-drug combinations, with the concentration of one or more drugs increasing 
along each direction of the plate. In the presence of the drugs, we grew the cells for 10-18 
h at 30 degrees C, with shaking at 1000 rpm on four identical vibrating plate shakers.  We 
measured the absorbance at 600 nm (A600) at time intervals dt (dt = 20 min for E. coli, 30 
min for S. aureus) using a Wallac Victor-2 1420 Multilabel Counter (Perkin Elmer) 
combined with an automated robotic system (Twister II, Caliper Life Sciences) to 
transfer plates between shakers and the reader.   
 
Growth Rate Calculation   13
From the time series of A600, we determined growth rates by fitting the early exponential 
phase portion of curves (0.01 < A600 <0.1) to an exponential function (MATLAB 7.6.0 
curve fitting toolbox, The Mathworks).  We normalized growth rates in the presence of 
single drugs (gi) or multiple drugs (gij, gijk, gijkl) by the growth rate of cells in the absence 
of drugs.  An example growth curve is shown in Figure S2.  Standard errors of the fitted 
growth parameter are used to estimate uncertainty in growth rates. 
 
To minimize the small effects of day-to-day fluctuations in drug efficacy (typically <5%), 
we generated a standard dose-response curve (and IC50 value) for each drug by 
combining all data involving only exposure to that drug.  In all subsequent three and four-
drug experiments, we re-measured the IC50 value for each drug and scaled all 
concentrations to ensure it agreed with the IC50 from the standard curve.  Single drug (gi) 
and pairwise (gij) growth rates at a given set of concentrations were then estimated by 
interpolating, if necessary, between data points measured at nearby concentrations.  
  
 
 Acknowledgements 
We thank C. Guet, L. Bruneaux, E. Balleza and A. Subramaniam for technical guidance 
and Ilya Nemenman, Jonathon D. Shlens, Remi Monasson, Simona Cocco, Kris Wood, 
and all members of the Cluzel lab for many helpful discussions. We also thank K. Dave 
for editorial advice and assistance. This work was supported in part by the NIH award 
P50GM081892-02 to the University of Chicago and the NSF Postdoctoral Fellowship 
0805462 (to K.W.).   
 
 
 
 
 
 
 
 
   14
 
 
 
 
 
References 
 
1. Baddour,  L.M. et al. Infective endocarditis: diagnosis, antimicrobial therapy, and 
management of complications: a statement for healthcare professionals from the 
Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on 
Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, 
Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: 
endorsed by the Infectious Diseases Society of America. Circulation 111, e394-
434 (2005). 
2.  Deresinski, S. Vancomycin in combination with other antibiotics for the treatment 
of serious methicillin-resistant Staphylococcus aureus infections. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of 
America 49, 1072-9 (2009). 
3. Herbert,  D. et al. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, 
and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium 
tuberculosis. Antimicrobial agents and chemotherapy 40, 2296-9 (1996). 
4.  Mory, F., Fougnot, S., Rabaud, C., Schuhmacher, H. & Lozniewski, A. In vitro 
activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other 
antibiotics alone and in combination against Propionibacterium acnes isolates 
from central nervous system infections. The Journal of antimicrobial 
chemotherapy 55, 265-8 (2005). 
5.  Bliss, C.I. The calculation of microbial assays. Bacteriological reviews 20, 243-
58 (1956). 
6.  Loewe, S. The problem of synergism and antagonism of combined drugs. 
Arzneimittel-Forschung 3, 285-90 (1953). 
7.  Greco, W.R., Bravo, G. & Parsons, J.C. The search for synergy: a critical review 
from a response surface perspective. Pharmacol Rev 47, 331-85 (1995). 
8.  Bollenbach, T., Quan, S., Chait, R. & Kishony, R. Nonoptimal microbial response 
to antibiotics underlies suppressive drug interactions. Cell 139, 707-18 (2009). 
9.  Huovinen, P., Wolfson, J.S. & Hooper, D.C. Synergism of trimethoprim and 
ciprofloxacin in vitro against clinical bacterial isolates. European journal of 
clinical microbiology & infectious diseases : official publication of the European 
Society of Clinical Microbiology 11, 255-7 (1992). 
10.  Cover, T.M. & Thomas, J.A. Elements of information theory, xxiii, 748 p. (Wiley-
Interscience, Hoboken, N.J., 2006). 
11.  Jaynes, E.T. Information Theory and Statistical Mechanics. Physical Review 106, 
620-630 (1957).   15
12.  Isserlis, L. On a formula for the product-moment coefficient of any order of a 
normal frequency distribution in any number of variables. Biometrika 12, 134-139 
(1918). 
13.  Langlois, R., Cantor, C.R., Vince, R. & Pestka, S. Interaction between the 
erythromycin and chloramphenicol binding sites on the Escherichica coli 
ribosome. Biochemistry 16, 2349-56 (1977). 
14.  Cohen, S.P., Levy, S.B., Foulds, J. & Rosner, J.L. Salicylate induction of 
antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-
independent pathway. Journal of bacteriology 175, 7856-62 (1993). 
15.  Haight, T.H. & Finland, M. Laboratory and clinical studies on erythromycin. The 
New England journal of medicine 247, 227-32 (1952). 
16.  Amari, S. Information geometry on hierarchy of probability distributions. Ieee 
Transactions on Information Theory 47, 1701-1711 (2001). 
17.  Schneidman, E., Still, S., Berry, M.J., 2nd & Bialek, W. Network information and 
connected correlations. Physical review letters 91, 238701 (2003). 
18.  Fitzgerald, J.B., Schoeberl, B., Nielsen, U.B. & Sorger, P.K. Systems biology and 
combination therapy in the quest for clinical efficacy. Nat Chem Biol 2, 458-66 
(2006). 
19.  Jonker, D.M., Visser, S.A.G., van der Graaf, P.H., Voskuyl, R.A. & Danhof, M. 
Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions 
in vivo. Pharmacology & Therapeutics 106, 1-18 (2005). 
20.  Keith, C.T., Borisy, A.A. & Stockwell, B.R. Multicomponent therapeutics for 
networked systems. Nat Rev Drug Discov 4, 71-8 (2005). 
21.  Kohanski, M.A., Dwyer, D.J. & Collins, J.J. How antibiotics kill bacteria: from 
targets to networks. Nature reviews. Microbiology 8, 423-35 (2010). 
22.  Lehar, J., Stockwell, B.R., Giaever, G. & Nislow, C. Combination chemical 
genetics. Nature chemical biology 4, 674-81 (2008). 
23. Lehar,  J. et al. Chemical combination effects predict connectivity in biological 
systems. Molecular systems biology 3, 80 (2007). 
24. Geva-Zatorsky,  N. et al. Protein dynamics in drug combinations: a linear 
superposition of individual-drug responses. Cell 140, 643-51 (2010). 
25. Margolin,  A.A. et al. ARACNE: an algorithm for the reconstruction of gene 
regulatory networks in a mammalian cellular context. BMC bioinformatics 7 
Suppl 1, S7 (2006). 
26.  Mora, T., Walczak, A.M., Bialek, W. & Callan, C.G., Jr. Maximum entropy 
models for antibody diversity. Proceedings of the National Academy of Sciences 
of the United States of America 107, 5405-10 (2010). 
27. Shlens,  J. et al. The structure of large-scale synchronized firing in primate retina. 
The Journal of neuroscience : the official journal of the Society for Neuroscience 
29, 5022-31 (2009). 
28. Shlens,  J. et al. The structure of multi-neuron firing patterns in primate retina. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 26, 
8254-66 (2006). 
29.  Schneidman, E., Berry, M.J., 2nd, Segev, R. & Bialek, W. Weak pairwise 
correlations imply strongly correlated network states in a neural population. 
Nature 440, 1007-12 (2006).   16
30.  Chatterjee, M.S., Purvis, J.E., Brass, L.F. & Diamond, S.L. Pairwise agonist 
scanning predicts cellular signaling responses to combinatorial stimuli. Nature 
biotechnology 28, 727-32 (2010). 
31. Baba,  T. et al. Construction of Escherichia coli K-12 in-frame, single-gene 
knockout mutants: the Keio collection. Molecular systems biology 2, 2006 0008 
(2006). 
32.  Baba, T., Bae, T., Schneewind, O., Takeuchi, F. & Hiramatsu, K. Genome 
sequence of Staphylococcus aureus strain Newman and comparative analysis of 
staphylococcal genomes: polymorphism and evolution of two major pathogenicity 
islands. Journal of bacteriology 190, 300-10 (2008). 
 
 
 
 
 
Figure Legends 
 
Fig. 1.  Growth in response to multiple drugs can be predicted from the growth in 
response to those drugs singly and in pairs using maximum entropy (A) Schematic 
axes showing that the normalized growth responses of bacteria to pairs of drugs (g12, g23, 
g13) are used to predict the normalized growth response to all three drugs (g123).  We use 
the three-drug case as an example; but growth in response to any number (N) of drugs 
can be predicted, as long as we know all pairwise responses.  (B) We estimate growth in 
the presence of drugs using nonlinear least squares fitting to optical density time series. 
For each drug i, we define a random variable Xi whose expectation value is equal to the 
growth gi.  (C) We made predictions by first estimating the maximum entropy 
distribution, P, using growth rate data from cells exposed to single drugs and drug pairs.  
The distribution takes an exponential form parameterized by resilience coefficients (hi, 
blue circles) and drug-drug coupling coefficients (Jij, pink boxes) that characterize the 
single drug response and the response to pairs of drugs, respectively. The resilience and 
coupling coefficients are chosen to ensure the moments, <Xi> and <XiXj>, of Ppair match 
the two-drug growth rate data at each drug dosage.  After determining the maximum 
entropy distribution, the N-drug growth response can be predicted by calculating the 
expectation values of the product X1X2...XN.  We find that these expectation values are   17
related to the moments <Xi> and <XiXj> by simple algebraic expressions (Supporting 
Information). 
 
 
 
 
 
 
 
 
Fig. 2. Three- and 4-Drug Interactions Arise from the Accumulation of Pairwise 
Interactions. Maximum entropy predictions of growth, using only data from pairwise 
drug interactions, match experimental growth responses in E. coli (A-C) and S. aureus 
(D) in the presence of 3- (A, B, D) and 4-drug combinations (C).  In each panel, lower 
insets are heat maps showing the model’s predictions (left) and experimental data (right) 
for various planes through the three- or four-dimensional spaces of drug concentrations. 
White squares indicate drug dosages for which the maximum entropy algorithm did not 
converge.  Experimental error bars, 95% confidence intervals from nonlinear fitting; 
Error bars on predictions, +/- 2 standard deviations of an ensemble of predictions from 
maximum entropy distributions calculated with random initial conditions (Supporting 
Information). Cm, chloramphenicol; Dox, doxycycline; Ery, erythromycin; Kan, 
kanamycin; Linc, lincomycin; Ofl, ofloxacin; Sal, salicylate; Tet, tetracycline; Tmp, 
trimethoprim. 
 
 
 
 
 
 
   18
Fig. 3. Predictions Highlight Ways That Pairwise Interactions Accumulate to Yield 
Higher-Order Interactions Total drug interactions and pairwise drug interactions for 3-
drug (A-D) and 4-drug combinations (E, F) in E. coli (A-C, E, F) and S. aureus (D). Each 
panel shows pairwise (all panels, left, I-ij = gij-gigj and three-drug (A-D, right, g123-
g1g2g3) or four-drug (E-F,right, g1234-g1g2g3g4) interactions at a given drug dosage.  Light 
bars, maximum entropy prediction; dark bars, experimental result.  Shaded portions of 
each plot indicate regions of approximately additive behavior (add, |interaction| < 0.1).  
In all panels, antagonism (antag) and synergy (syn) labels correspond to interactions of 
+0.3 and -0.3, respectively.  Error bars, +/- standard error (Supporting Information).   
Interactions that cannot be statistically explained from the pairwise predictions are less 
than 0.05 (units of relative growth rate) in all cases (see also Figure S18).  Drug 
combinations:  A, Chloramphenicol-Erythromycin-Trimethoprim; B, Chloramphenicol-
Ofloxacin-Trimethoprim; C, Chloramphenicol-Ofloxacin-Salicylate; D, Kanamycin-
Erythromycin-Tetracycline; E, Doxycycline-Erythromycin-Lincomycin-Salicylate; F, 
Chloramphenicol-Ofloxacin-Trimethoprim-Lincomycin. 
Table Legends 
 
Table 1.  Comparison of Pairwise Approximation with Independent Model 
Coefficient of determination, R
2, is defined as R
2 = 1-SSerr / SStot, where SSerr is the 
residual sum of squares between model and data, and SStot is the total sum of squares 
(proportional to the variance of the experimental measurements).  ΔAIC is the difference 
in AIC values between the pairwise and the independent model.  The last column 
provides the Akaike weight in favor of the pairwise model (Supporting Online Material). 
** R
2<0, which indicates very poor fit (the mean of the data provides a better fit than the 
model) 
 
Table 2.  Validation of Pairwise Approximation.  fc represents the fraction of total 
three-drug correlations that are captured by the pairwise model.  For each drug dosage 
containing nonzero amounts of all three drugs, we calculated the maximum entropy 
distributions PN (N=1,2,3), which are consistent with all measurements involving N or   19
fewer drugs.  We then calculated the multi-information I3 = S1 - S3 , where Si is the 
entropy of the distribution Pi.   The fraction of total correlations captured by the pairwise 
model is then 
fc ≡
I2 
I3 
 
where sums run over all data points for a given 3-drug combination.  An fc of 1 would 
indicate that the pairwise model captured all higher-order correlations or, equivalently, 
that interactions involving exactly N drugs (for N>2) do not contribute to the multi-drug 
effects. Cm, chloramphenicol; Dox, doxycycline; Ery, erythromycin; Kan, kanamycin; 
Linc, lincomycin; Ofl, ofloxacin; Sal, salicylate . Tet, tetracycline; Tmp, trimethoprim.  
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Table 1: 
 
Drug 
Combination 
R
2 
(Pairwise) 
R
2
(Independent) 
ΔAIC  Weight for 
Pairwise 
Sal-Ery-Cm  0.93  0.82  -109.0  > 0.999 
Cm-Ery-Tmp  0.87  0.87  -5.9  0.95 
Cm-Ofl-Sal  0.74  **  -909.4  > 0.999 
Cm-Ofl-Tmp  0.90  0.87  -14.4  > 0.999 
Dox-Ery-Linc  0.86  0.88  51.5  < 0.001 
Dox-Ery-
Linc-Sal 
0.72  **  -161.6  > 0.999 
Linc-Cm-Ofl-
Tmp 
0.85  0.70  -83.4  > 0.999 
All Data  0.90  0.33  -2233.2  > 0.999 
 
  
Table 2: 
 
Drug Combination  fc
E. coli 
Sal-Ery-Cm  0.95 
Cm-Ery-Tmp  0.89  
Cm-Ofl-Sal  0.98 
Cm-Ofl-Tmp  0.95 
Dox-Ery-Linc  0.94 
S. aureus 
Tet-Kan-Ery  0.93 
Total (All Drugs) 0.97 
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


 
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

 


 


























Figure S1: Table of Drugs, with corresponding classes and modes of action.
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A table of all drugs used is shown in Figure S1, and an example growth curve
is shown in Figures S2.
20 100 200 300 400 500
10
−3
10
−2
10
−1
time (minutes)
A
b
s
o
r
b
a
n
c
e
 
a
t
 
6
0
0
 
n
m
Figure S2: Growth Rate Measurement. Time series of A600 vs. time. Solid line,
ﬁt to exponential function. Dashed lines, region of exponential growth. Growth
rate is given by the slope of the line.
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2.1 Statistical Framework for Drug Combinations
The ultimate goal of our analysis is to establish a predictive relationship be-
tween the e ects of small drug combinations (1- or 2-drug combinations) and
the e ects of larger multi-drug combinations. Because mechanistic models for
large intracellular networks are often not tractable, we introduce a statistical
framework which, by construction, associates drug interactions to correlations
between stochastic variables. The model o ers one way of establishing testable
predictions by ﬁrst mapping experimental measurements to moments of a joint
probability distribution. The problem is then reduced to estimating theu n -
known distribution, which can be achieved using statistical techniques, such
as entropy maximization, or (in principle) by incorporating other assumptions
about the underlying physical system.
Speciﬁcally, we assume that interactions between N drugs can be modeled
as correlations between N continuous stochastic variables, Xi,(i =1 ...N), such
that the observed growth of cells (g1,2..N) in the presence of N drugs is given by
g1,2..N =  X1X2...XN  (S1)
where brackets represent an expectation value over an ensemble described by
the unknown probability density P(x1,x 2,...xN). If the variables Xi are uncor-
related, the growth reduces to a product
g1,2..N =  X1  X2 ... XN  g1g2...gN, (S2)
3which is equivalent to Bliss independence, a common phenomenological model
used in pharmacology to describe non-interacting drugs [2].
We would like to ask whether pairwise interactions between drugs can be
used to predict the e ects of larger combinations of drugs. Within the above
framework, predicting e ects of drug combinations reduces to estimating mo-
ments of the unknown distribution P(x1,x 2,...xN) using data on interactions
between pairs of drugs. Therefore, to test our hypothesis, we must estimate
higher-order moments of P(x1,x 2,...xN) (the e ects of a multi-drug combina-
tion) using only the lower order moments (the e ects of two-drug combinations).
The question, then, is how does one estimate, without mechanistic assumptions
or a physical model, the unknown probability distribution P(x1,x 2,...xN) given
only information about some collection of moments of that distribution,
 fj  
  b
a
  b
a
...
  b
a
P(x1,x 2,...xN)fj(x1,x 2,...xN)dx1dx2...dxN =  j. (S3)
Entropy maximization o ers one method of solving this problem by choosing
a distribution consistent with known moments but that does not incorporate
additional statistical structure [18, 19, 33].
In what follows, we restrict ourselves for illustrative purposes to the three-
drug case, though the results are easily generalizable to any larger drug combi-
nation. To estimate P(x1,x 2,x 3), we maximize the entropy, S(P), subject to
the known moment constrains. The entropy, S(P), is deﬁned (up to an additive
constant) as
S(P)= 
  b
a
  b
a
  b
a
P(x1,x 2,x 3)log
 
P(x1,x 2,x 3)
q(x1,x 2,x 3)
 
dx1dx2dx3, (S4)
where q(x1,x 2,x 3) is a continuous prior distribution that accounts for an a priori
knowledge gleaned from, for example, physical considerations or experience.
The maximization amounts to minimizing the Kullback-Leibler divergence [35]
between the distributions P and q, subject to constraints on the moments. We
choose the interval [a,b] to be ﬁnite and take q(x1,x 2,x 3)t ob eac o n s t a n t ,
which is equivalent to assuming a uniform prior distribution. We stress that
our results do not depend on a speciﬁc choice of [a,b], as long as some minimal
conditions are met (see below).
To proceed with the estimation of P(x1,x 2,x 3), we ﬁrst measured the growth
response to each drug i alone (gi) and to all pairs of drugs, (gij). To predict the
e ects of a given three-drug combination, for example, we measured g1, g2, g3,
4g12, g13,a n dg23. The corresponding constraints on the distribution are simply
 f1  
  b
a
  b
a
  b
a
P(x1,x 2,x 3)x1dx1dx2dx3 = g1,
 f2  
  b
a
  b
a
  b
a
P(x1,x 2,x 3)x2dx1dx2dx3 = g2,
 f3  
  b
a
  b
a
  b
a
P(x1,x 2,x 3)x3dx1dx2dx3 = g3,
 f4  
  b
a
  b
a
  b
a
P(x1,x 2,x 3)x1x2dx1dx2dx3 = g12,
 f5  
  b
a
  b
a
  b
a
P(x1,x 2,x 3)x1x3dx1dx2dx3 = g13,
 f6  
  b
a
  b
a
  b
a
P(x1,x 2,x 3)x2x3dx1dx2dx3 = g23.
(S5)
We can use Lagrange multipliers ( 0,h 1,h 2,h 3,J 12,J 13,J 23) to maximize
the entropy S(P) subject to these constraints, which leads to
P(x1,x 2,x 3)=
1
Z
exp(h1x1 + h2x2 + h3x3 + J12x1x2 + J13x1x3 + J23x2x3),
(S6)
where Z is a constant (related to  0) that normalizes the distribution. It can
be shown that, in general, the entropy of a distribution calculated in this way
corresponds to the global maximum, if it exists [19],[33].
We have labeled the Lagrange multipliers as hi and Jij in accordance with
notation commonly used for the well-known Ising model, which takes a similar
form [36]. In the context of our drug interaction model, hi encodes the single-
drug growth response and Jij encodes information about deviations from Bliss
independence for a given drug pair, with Jij > 0 indicating antagonism and
Jij < 0 indicating synergy. We call the parameter hi the resilience coe cient
and Jij the drug-drug coupling coe cient between the drugs i and j; they char-
acterize the response to single drugs and to pairs of drugs, respectively (Fig.
S3). Intuitively, the value of the resilience coe cient reﬂects the cell growth in
response to a given concentration of one drug (Fig. S3). The resilience coef-
ﬁcient decreases with increasing drug concentration. The drug-drug coupling
coe cient, J, reﬂects, for each drug dosage, the nature of interactions taking
place between two given drugs (Fig. S3). For example, when J is zero, there
exists no drug-drug coupling and the two drugs act independently. When J
is positive, the drug pair is antagonistic and for negative values, the pair is
synergistic.
2.1.1 Growth Rate Predictions and Uncertainties
In practice, we calculate the parameters hi and Jij from experimental data
using a standard numerical technique that involves minimizing a dual space
5Lagrangian [37]. The minimization occurs on a convex surface and can be ac-
complished with any unconstrained optimization algorithm. For each dosage of
a given three- or four-drug combination, we performed the optimization 50 times
(for 3 drugs) or 25 times (for four drugs) starting from random initial conditions
drawn from a uniform distribution on the interval [ 0.5,0.5]. Nonphysical pre-
dictions (g<0, g>1) occasionally arise from strongly synergistic or strongly
antagonistic combinations, and these are set to 0 (no growth) or 1 (maximum
growth), respectively. While the minimization should not be prone to errors
due to local minima, we ﬁnd that ﬁts of similar quality can be achieved using
a range of parameter values; hence, there is some uncertainty in the location
of the true minimum. Taking random initial conditions allows us to estimate
this uncertainty and o er more reliable predictions. All predictions represent
the mean of these trials. Error bars of the growth predictions in Figure 3 are
±2 , with   the standard deviation of the distribution of trials. Standard errors
of the mean, which are between 5 and 8 times smaller, could be used instead
to give a true estimate of the error associated with each prediction,b u tt h e y
leave the reader without a sense of  . Uncertainties in the prediction of drug
interactions, I1..N   g12..N   g1g2...gN, (Figure 4) must incorporate standard
errors from single drug measurements (gi). Therefore, the error bars represent
± 1 standard error of the mean. For distributions of 25 or 50 trials, the standard
error associated with the prediction of the ﬁrst term (g12..N) is much smaller
than that of the second term (g1g2...gN). Uncertainties of the drug interaction
predictions are therefore dominated by standard errors in the estimates of single
drug growth rates gi appearing in the second term.
2.1.2 Choosing the State Space
The calculation of the maximum entropy distribution requires a speciﬁc choice
of state space, [a,b], for each continuous stochastic variable Xi. First, we note
that if the boundaries are chosen such that [a,b]=[   , ] - that is, the
variables take values on the real line - a (normalizable) distribution of the form
Equation S6 does not exist, because there are no constraints on the variances,
 X2
i  . In practice, this di culty can be circumvented by choosing [a,b]t ob e
ﬁnite, which puts implicit limits on the variance of each variable. While this
amounts to an additional assumption, we ﬁnd empirically that the predictions of
higher moments from lower moments do not depend on the choice [a,b] as long
as i) the distribution of the form Equation S6 is normalizable and ii) a solution
to Equations S5, S6 can be found for some choice of Lagrange multipliers. The
speciﬁc values of the Lagrange multipliers will of course depend on the choice of
state space, but the relationship between higher moments and lowerm o m e n t s
conforms to that given by Issesrlis’ theorem in all cases where a suitable solution
to Equation 5 is found. We return to this point below.
Figures S4, S5 illustrate the ﬁt of models with di erent choices of (a,b)t o
all two-drug and single drug data. We note that these are not predictions, but
simply ﬁts to examine whether a solution to Equations S5, S6 can be found.
Figure S4 illustrates that choices with (a,b)=( 0 ,b)f o rb>0 do not provide
6an accurate description of many of the measured drug interactions; that is, a
valid solution cannot be found. On the other hand, the ﬁt improves signiﬁcantly
when a<0a n db>0 (Figure S5). For su ciently large |b   a|, the ﬁt again
becomes poor, likely because of the failure of numerical integration over the
increasingly large state space. Hence, for all three-drug calculations, we choose
(a,b)=(  3,4) (Figure S5, lower left panel), which provides an excellent ﬁt
(R2 > 0.99) to the pairwise data, indicating that a solution to Equations S5, S6
is achievable. This choice is not unique, and other choices (e.g. (a,b)=(  9,10))
are possible but must utilize more computational resources to calculate integrals
at the same level of accuracy. For similar reasons, we choose a smaller range
(a,b)=(  1,2) for four-drug predictions to allow for faster computation of the
numerical integrals. The ﬁnal predictions do not depend on these choices of
state space, but instead only on the measured growth rates for drug pairs and
single drugs. The exact same results are also obtained if we choose the variables
to be discrete ”spin-like” variables, as long as the value of the spin is su ciently
large (e.g. spin = ±4). In the latter case, the integrals become sums that are
easily calculated.
2.1.3 Example Maximum Entropy Distributions
We illustrate example (marginal) maximum entropy distributions calculated
for the drug combination salicylate, erythromycin, and chloramphenicol in Fig-
ures S6, S7. Figure S6 shows the pairwise, P2(x1,x 2)  
  b
a P(x1,x 2,x 3)dx3 ,
and single variable, P1(x1)  
  b
a P(x1,x 2,x 3)dx3dx2, marginal distributions for
the three-drug combination at a given dose of each drug. In this ﬁgure, the
concentration of chloramphenicol is 0, so these distributions describe the e ects
of salicylate and erythromycin alone (right panels) and in combination (left
panel). Similarly, Figure S7 shows the pairwise and single variable marginal
distributions for erythromycin and chloramphenicol in the absence of salicylate.
Deviations from the uniform distribution ensure that the experimental measure-
ments of pairwise drug interactions (2-body correlations) and single-drug e ects
(single variable means) are appropriately described by expectation values of P.
2.1.4 Isserlis’ Theorem Describes Observed Moment Relationships
Empirically, we ﬁnd that the moment relationships derived from our experiments
are consistent with the well-known Isserlis’ formula [38],
 XiXjXk  =  Xi  XjXk + Xj  XiXk + Xk  XiXj  2 Xi  Xj  Xk , (S7)
or in terms of the growth measurements,
gijk = gigjk + gjgik + gkgij   2gigjgk. (S8)
Similar expressions hold for higher order moments. For example,
gijkl = gilgjk + gikgjl + gijgkl   2gigjgkgl. (S9)
7Isserlis’ equations were originally proven for jointly distributed Gaussian vari-
ables, but they have also been extended to certain classes of non-Gaussian vari-
ables [39]. These relationships can be derived from the maximum entropy re-
sults using ﬁrst order perturbation theory when the drug-drug coupling is small
compared to the single drug e ects; they are exact if the distribution P(x) is
Gaussian. The result (Figure S8) is perhaps not surprising, given that the choice
of ﬁnite [a,b] implicitly constrains the variance of the distributions.
Consider, for example, that the same relationship can also be achieved in the
following way. Assume that the variables are constrained such that  X2
i   =  2
i
for some choice of constants  2
i > 0. Under these conditions, the maximum
entropy distribution for variables deﬁned on the real line is a Gaussian [33].
Therefore, Isserlis’ theorem will describe the moment relationships, and the
result will not depend on the speciﬁc choices of  2
i , as long as they are su ciently
large that a distribution satisfying all moment constraints exists.
The success of Equation S8 and, more generally, Isserlis’ theorem in pre-
dicting the e ects of large drug combinations is, in itself, a striking result. It
suggests that one could arrive at the same predictions by assuming,a tt h e
outset, that the variables Xi come from a multi-variate Gaussian distribution.
Such a relationship could arise, for example, from the Central Limit Theorem
if one could argue that the underlying stochasticity of intracellular networks
contributing to the multi-drug response arises from a sum of independent, or
nearly independent, stochastic variables. This remains an open question for
future work. Nevertheless, in practice, the simplicity of the algebraic expres-
sions given by Isserlis renders the method useful even to those without extensive
computational resources or experience.
2.1.5 Drug With Itself
In pharmacology, Bliss independence is well-known to be a poor model for the
e ects of a two drugs with highly similar mechanisms. In particular, it is of-
ten noted that Bliss independence cannot accurately describe an experiment
where a drug is divided into two volumes which are then combined (i.e. the
“interactions” of a drug with itself). Our results extend Bliss independence to
account for interactions between drug pairs, which raises the question of whether
the model can more accurately describe the “interaction” of a drug with itself.
Applying equation 8 to a such a scenario, we have
g(c1 + c2 + c3)= g(c1)g(c2 + c3)+g(c2)g(c1 + c3)+
g(c3)g(c1 + c2)   2g(c1)g(c2)g(c3),
(S10)
where g(x) is the growth in the presence of a drug at a concentration x.O n e
solution to this equation is given by an exponential function, which is a reason-
able model for the dose-response curve of many drugs over limited concentration
ranges. However, dose-response curves are typically modeled with a Hill func-
tion, g(x)=( 1+( x/K)n) 1, which is consistent with our single-drug data but
is not a solution of equation S10. To explore the usefulness of equation S10 for
8describing typical Hill-like dose-response relationships, we consider Hill func-
tions with Hill coe cients of n =1 ,n =2 ,a n dn =5( a n dK = 1 without loss
of generality). We then compare the predictions of equation S10 andt h ep r e -
dictions of Bliss independence (given by g(c1 +c2 +c3)=g(c1)g(c2)g(c3)) with
the true Hill function (Figure S9). The pairwise model signiﬁcantly improves
upon Bliss independence, especially when Hill coe cients are near 1, but it can
not perfectly capture steep features of the dose-response curve for larger n and
high drug dosages. These results suggest that the model may lose accuracy at
high dosages when drug combinations involve drugs with identical mechanisms
of action and steep dose-response curves. In practice, we ﬁnd that dose response
curves rarely have n>2, and furthermore, the method works well even when
drugs have similar–but not identical–modes of action (See Dox-Ery-Linc combo
in main text, Figure 3). Therefore, this theoretical limitation is unlikely to be
relevant in most practical situations.
2.2 Failure and Success of Bliss Independent Model
While our pairwise model performs signiﬁcantly better, on the whole, than the
Bliss independent model, we found that some combinations of three drugs may
nevertheless be appropriately modeled with Bliss independence. Figure S10
compares predictions from Bliss independence (left) with those from the pair-
wise model (right) for two 3-drug combinations. In the top drug combination
(Cm-Oﬂ-Sal), the pairwise approximation signiﬁcantly outperforms the inde-
pendent model. On the other hand, in the lower panels (Dox-Ery-Linc), the
results from both models are highly correlated (r   0.95) and both provide
reasonable ﬁts to the data. The latter result is particularly interesting given
the strong interactions that take place between doxycycline-lincomycin (strong
suppression) and doxycyline-erythromycin (strong synergy) when used in pairs
(see Figure 2).
2.3 Akaike Information Criteria and Model Selection
To statistically compare the pairwise model with the independent model, we
use standard model-selection techniques [40] (see Table 1 for results). Specif-
ically, we assume that the experimental errors are independent and Gaussian
distributed with unknown variance  2. We conﬁrm approximate normality of
residuals in Figure S11. We then calculate for each model the Akaike Informa-
tion Criteria, which is given by
AIC =  2log(L(ˆ c|y)) + 2n (S11)
where log(L(ˆ c|y)) is the log likelihood function, y is the data, c is maximum
likelihood estimate of the free parameters of the model (in this case,  2), and
n is the number of free parameters (n = 1 for both models, corresponding
to the unknown error variance). The AIC is an estimate of the expectation
value of the relative Kullback-Leibler (KL) divergence between the ﬁtted model
9and the “true mechanism” generating the observed data. The model with the
lowest AIC value among a set of models is considered the best model in that
it minimizes the KL divergence between the model and statistical mechanism
underlying the data. For independent Gaussian errors, AIC reduces (up to an
additive constant) to
AIC =  N log(ˆ  2)+2 n, (S12)
where N is the number of observations and ˆ  2 is the maximum likelihood esti-
mate of the variance. In practice, we use a small sample estimator ofA I Ct h a t
includes a bias correction term
AIC =  2log(L(ˆ c|y)) + 2n +
2n(n +1 )
N   n   1
. (S13)
The di erences in AIC values between the pairwise model and the Bliss inde-
pendent model can be converted to an Akaiki weight in favor of the pairwise
model,
w =
exp(  /2)
exp(  /2) + 1
(S14)
where     AICpair   AICind.B e c a u s ee x p (   /2) is proportional to the likeli-
hood of the pairwise model given the data, the weight w can be interpreted as
a measure of the evidence in favor of the pairwise model as the best of the two
models.
2.4 Predictions of 3-Drug and 4-Drug E ects
Figures S12 - S16 show predictions for three-drug (Figures S12 - S15) and four-
drug (Figure S16) combinations calculated using the maximum entropy distri-
butions (or, equivalently, using Equation S7). Each ﬁgure includes heat maps
comparing experimental growth to theoretical predictions (left hand side) as
well as a direct comparison of predictions vs. experiments.
2.5 Combinatorial Experiments Testing 3-Drug Predic-
tions
In addition to exploring the entire space of 3-drug concentrations for the drug
combinations listed above, we have also performed combinatorial experiments to
test the predictions of our model on a broad range of 3-drug combinations, each
at a single dosage. Each combinatorial experiment involves N drugs, each at a
single concentration, D1,D 2,...DN. In each experiment, we test all
 N
3
 
possible
3-drug combinations and compare the experimental results to predictions from
our pairwise model. We choose N to be 5, 6, or 7 and performed 5 combinatorial
experiments yielding a total of 93 unique 3-drug combinations and 120 unique
dosage combinations.
A table of all drug combinations is shown at the end of the SI document, and
the corresponding comparisons between predictions and experiment are shown
in Figures S17, S18 (inset, which includes error bars). The pairwise model
10performs remarkably well (R2 =0 .95) and signiﬁcantly outperforms the naive
independence model (R2 =0 .29), which demonstrates the need to account for
pairwise interactions.
To estimate the frequency of pure 3-body interactions, we also include a his-
togram (Figure S18, main ﬁgure) of the statistical deviations from the pairwise
predictions. These deviations, which cannot be statistically explainedb yt h e
pairwise approximation, occur when the 95 percent conﬁdence interval of the
di erence   = gexp   gpred,w h e r egexp is the relative growth from experiment
and gpred is the predicted relative growth, does not contain 0. The di erence
between the boundary of this conﬁdence interval and 0 is deﬁned tob et h e
deviation,  I3 (units are relative growth rate); this deviation may arise from
pure 3-drug interactions. In 74 of the 120 drug combinations, the deviation is
zero ( I3 = 0). In the remaining 46 combinations, the deviations (unexplained
drug interactions) are very small (mean= 0.034±0.005), with the maximum of
 I3,max =0 .12.
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Figure S3: Experimentally determined growth rates, resilience coe cients (h),
and coupling coe cients (J), of maximum entropy distribution for pairwise
drug interactions. Growth rate data and maximum entropy coe cients for drug
pairs (A) Doxycycline-Erythromycin (synergistic), (B) Doxycycline-Lincomycin
(weakly antagonistic), and (C) Erythromycin-Lincomycin (strongly antagonis-
tic). In each panel, top plots show heat maps of cell growth in the presence
of two drugs. Cell growth is normalized by growth in the absence of drugs.
Warmer colors indicate high growth rates, whereas cooler colors indicate slower
growth rates. Bottom left, resilience coe cients, h, as a function of each drug
in the combination. Decreasing the resilience coe cient, h, corresponds to a
decrease in growth rate. Error bars: standard error of replicates (smaller than
data points). Bottom right, drug-drug coupling coe cients, J, as a function of
drug concentration for each drug pair. J>0 corresponds to antagonism, J<0
to synergy, and J = 0 to additivity. 120 0.5 1
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Figure S4: Fitting two-drug Data Using State Spaces with a =0 ,b>0. Upper
left, b = 1, upper right, b = 3, lower left, b = 5, lower right, b = 5. Di erent
symbols represent growth of cells in response to drug pairs drawn from di erent
three-drug combinations (Sal-Ery-Cm, squares; Cm-Ery-Tmp, circles; Cm-Oﬂ-
Sal, upright triangles; Cm-Oﬂ-Tmp, leftward triangles; Dox-Ery-Linc, stars).
Black lines, line of slope 1 indicating perfect ﬁt. Note that many data points in
the lower right panel fall outside of the range of the plots.
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Figure S5: Fitting two-drug Data Using State Spaces with a<0, b>0. Upper
left, (a,b)=(  0.5,1.5), upper right, (a,b)=(  2,3), lower left, (a,b)=(  3,4),
lower right, (a,b)=(  19,20). Di erent symbols represent growth of cells in re-
sponse to drug pairs drawn from di erent three-drug combinations (Sal-Ery-Cm,
squares; Cm-Ery-Tmp, circles; Cm-Oﬂ-Sal, upright triangles; Cm-Oﬂ-Tmp, left-
ward triangles; Dox-Ery-Linc, stars). Black lines, line of slope 1 indicating
perfect ﬁt.
13x
1 (Salicylate)
x
2
 
(
E
r
y
t
h
r
o
m
y
c
i
n
)
 
 
−2 0 2 4
−2
0
2
4
−4 −2 0 2 4
0.12
0.14
0.16
x
1 (Salicylate)
P
(
x
1
)
−4 −2 0 2 4
0.12
0.14
0.16
x
2 (Erythromycin)
P
(
x
2
)
0.019
0.02
0.021
0.022
0.023
Figure S6: Example Maximum Entropy Distrubitions: Pairwise,
P2(x1,x 2)  
  b
a P(x1,x 2,x 3)dx3 (left panel), and single variable,
P1(x1)  
  b
a P(x1,x 2,x 3)dx3dx2 (right panels), marginal distributions for
the three-drug combination salicylate (2 mM), erythromycin (25µg/mL), and
chloramphenicol (0µg/mL). Vertical dashed lines indicate averages  xi , which
correspond to single drug growth rates gi. Drugs are arbitrarily labeled as 1
(salicylate), 2 (erythromycin), and 3 (chloramphenicol).
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Figure S7: Example Maximum Entropy Distrubitions: Pairwise,
P2(x1,x 2)  
  b
a P(x1,x 2,x 3)dx3 (left panel), and single variable,
P1(x1)  
  b
a P(x1,x 2,x 3)dx3dx2 (right panels), marginal distributions for
the three-drug combination salicylate (0 mM), erythromycin (25µg/mL), and
chloramphenicol (1µg/mL). Vertical dashed lines indicate averages  xi , which
correspond to single drug growth rates gi. Drugs are arbitrarily labeled as 1
(erythromycin), 2 (chloramphenicol), and 3 (salicylate).
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Figure S8: Comparison of Moment Relationships given by Maximum Entropy
and Isserlis’ Theorem: Predictions of growth in the presence of three-drug (3rd
order moments) based on maximum entropy (x axis) and Isserlis’ theorem (y-
axis). Di erent colors represent di erent three-drug combinations.
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Figure S9: Drug With Itself. Predictions from Isserlis’ equation (open circles)
and Bliss independence (solid circles) for Hill function dose response curves
(solid line) with Hill coe cients n = 1 (left), n =2( c e n t e r ) ,a n dn = 5 (right).
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Pairwise Model Outperforms Independent Model (Cm−Ofl−Sal)
0 0.5 1
0
0.2
0.4
0.6
0.8
1
Growth (Prediction)
G
r
o
w
t
h
 
(
E
x
p
e
r
i
m
e
n
t
)
0 0.5 1
0
0.2
0.4
0.6
0.8
1
Independence Model Sufficient (Dox−Ery−Linc)
Growth (Prediction)
G
r
o
w
t
h
 
(
E
x
p
e
r
i
m
e
n
t
)
Independent
Independent
Pairwise
Pairwise
Figure S10: Comparison between independent model (left) and pairwise model
(right) for two three-drug combinations: chloramphenicol-oﬂoxacin-salicylate
(top) and doxycycline-erythromycin-lincomycin (bottom).
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Figure S11: Verifying Normality of Residuals. Main ﬁgure, Histogram of Resid-
uals from Pairwise Model (all drug combinations); red line, ﬁt to normal distri-
bution. Inset: Normal Probability Plot (straight line indicates normality).
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Figure S12: Comparison of Predictions with Experiments for the three-drug
combination Cm-Ery-Tmp.
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Figure S13: Comparison of Predictions with Experiments for the three-drug
combination Cm-Oﬂ-Tmp
0 0.5 1
0
0.5
1
Growth (Experiment)
G
r
o
w
t
h
 
(
P
r
e
d
i
c
t
i
o
n
) [Ofl],[Sal]
[
C
m
]
Prediction
[Ofl],[Sal]
[
C
m
]
Experiment
[Ofl],[Cm]
[
S
a
l
]
[Ofl],[Cm]
[
S
a
l
]
[Sal],[Cm]
[
O
f
l
]
[Sal],[Cm]
[
O
f
l
]
Figure S14: Comparison of Predictions with Experiments for the three-drug
combination Cm-Oﬂ-Sal
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Figure S15: Comparison of Predictions with Experiments for the three-drug
combination Dox-Ery-Linc
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Figure S16: Comparison of Predictions with Experiments for the four-drug
combination Dox-Ery-Linc-Sal
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Figure S17: Comparison of Predictions with Experiments for the 3-drug Combi-
natorial Experiments. Each number corresponds to a 3-drug combination from
the table at the end of the SI material.
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Figure S18: Histogram of Deviations from Pairwise Predictions. Deviations
from the pairwise predictions occur when the 95 percent conﬁdence interval
of the di erence   = gexp   gpred,w h e r egexp is the relative growth from ex-
periment and gpred is the predicted relative growth, does not contain 0. The
di erence between the boundary of this conﬁdence interval and 0 is deﬁned to
be the deviation from pairwise predictions (units are relative growth rate). In-
set: Comparison of Predictions with Experiments for the 3-drug Combinatorial
Experiments. Error bars are ± standard error.
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XW <$O/,P ) !57 *;*V <$%&Q4-0 (;)V
XU <$O/,P ) !57 *;*V M7/4# 8
XY <$O/,P ) !57 *;*V M7-1 )**
X8 <$O/,P ) <$%&Q4-0 (;)V M7/4# 8
V* <$O/,P ) <$%&Q4-0 (;)V M7-1 )**
V( <$O/,P ) M7/4# 8 M7-1 )**
V) !57 *;*V <$%&Q4-0 (;)V M7/4# 8
V9 !57 *;*V <$%&Q4-0 (;)V M7-1 )**
VX !57 *;*V M7/4# 8 M7-1 )**
VV <$%&Q4-0 (;)V M7/4# 8 M7-1 )**
K"56-,$#"1-$%&TH7/1-5/,#&9&>V&01+23AI&&Q57?&!"61?&<$%&Q4-0?&M7/4#?&M7-1
VW Q57 *;Y !"61 (;W <$%&Q4-0 (
VU Q57 *;Y !"61 (;W M7/4# Y
VY Q57 *;Y !"61 (;W M7-1 )**
V8 Q57 *;Y <$%&Q4-0 ( M7/4# Y
W* Q57 *;Y <$%&Q4-0 ( M7-1 )**
W( Q57 *;Y M7/4# Y M7-1 )**
W) !"61 (;W <$%&Q4-0 ( M7/4# Y
W9 !"61 (;W <$%&Q4-0 ( M7-1 )**:"#%$ *+,-&; <*+,-&;=&
>,-?0:@AA
*+,-&( <*+,-&(=&
>,-?0:@AA
*+,-&B <*+,-&B=&
>,-?0:@AA
WX !"61 (;W M7/4# Y M7-1 )**
WV <$%&Q4-0 ( M7/4# Y M7-1 )**
K"56-,$#"1-$%&TH7/1-5/,#&X&>U&01+23AI&&Q57?&K-7?&M+%'?&!57?&<$O/,P?&C"H?&K5
WW Q57 (;)V K-7 9;V M+%' (;V
WU Q57 (;)V K-7 9;V !57 *;(9
WY Q57 (;)V K-7 9;V <$O/,P (;V
W8 Q57 (;)V K-7 9;V C"H *;(V
U* Q57 (;)V K-7 9;V K5 *;V
U( Q57 (;)V M+%' (;V !57 *;(9
U) Q57 (;)V M+%' (;V <$O/,P (;V
U9 Q57 (;)V M+%' (;V C"H *;(V
UX Q57 (;)V M+%' (;V K5 *;V
UV Q57 (;)V !57 *;(9 <$O/,P (;V
UW Q57 (;)V !57 *;(9 C"H *;(V
UU Q57 (;)V !57 *;(9 K5 *;V
UY Q57 (;)V <$O/,P (;V C"H *;(V
U8 Q57 (;)V <$O/,P (;V K5 *;V
Y* Q57 (;)V C"H *;(V K5 *;V
Y( K-7 9;V M+%' (;V !57 *;(9
Y) K-7 9;V M+%' (;V <$O/,P (;V
Y9 K-7 9;V M+%' (;V C"H *;(V
YX K-7 9;V M+%' (;V K5 *;V
YV K-7 9;V !57 *;(9 <$O/,P (;V
YW K-7 9;V !57 *;(9 C"H *;(V
YU K-7 9;V !57 *;(9 K5 *;V
YY K-7 9;V <$O/,P (;V C"H *;(V
Y8 K-7 9;V <$O/,P (;V K5 *;V
8* K-7 9;V C"H *;(V K5 *;V
8( M+%' (;V !57 *;(9 <$O/,P (;V
8) M+%' (;V !57 *;(9 C"H *;(V
89 M+%' (;V !57 *;(9 K5 *;V
8X M+%' (;V <$O/,P (;V C"H *;(V
8V M+%' (;V <$O/,P (;V K5 *;V
8W M+%' (;V C"H *;(V K5 *;V
8U !57 *;(9 <$O/,P (;V C"H *;(V
8Y !57 *;(9 <$O/,P (;V K5 *;V
88 !57 *;(9 C"H *;(V K5 *;V
(** <$O/,P (;V C"H *;(V K5 *;V:"#%$ *+,-&; <*+,-&;=&
>,-?0:@AA
*+,-&( <*+,-&(=&
>,-?0:@AA
*+,-&B <*+,-&B=&
>,-?0:@AA
K"56-,$#"1-$%&TH7/1-5/,#&V&>W&01+23AI&&R/,S?&O$4?&M+%'?&C"H?&K-7?&K5
(*( R/,S )* O$4 )** M+%' );V
(*) R/,S )* O$4 )** C"H *;)V
(*9 R/,S )* O$4 )** K-7 V
(*X R/,S )* O$4 )** K5 *;X
(*V R/,S )* M+%' );V C"H *;)V
(*W R/,S )* M+%' );V K-7 V
(*U R/,S )* M+%' );V K5 *;X
(*Y R/,S )* C"H *;)V K-7 V
(*8 R/,S )* C"H *;)V K5 *;X
((* R/,S )* K-7 V K5 *;X
((( O$4 )** M+%' );V C"H *;)V
(() O$4 )** M+%' );V K-7 V
((9 O$4 )** M+%' );V K5 *;X
((X O$4 )** C"H *;)V K-7 V
((V O$4 )** C"H *;)V K5 *;X
((W O$4 )** K-7 V K5 *;X
((U M+%' );V C"H *;)V K-7 V
((Y M+%' );V C"H *;)V K5 *;X
((8 M+%' *;)V K-7 V K5 *;X
()* C"H *;)V K-7 V K5 *;X